FOLFOX (mFOLFOX6)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OXALIPLATIN` `DRUG-LEUCOVORIN` `DRUG-5-FLUOROURACIL`

ID	`REG-FOLFOX`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

Standard adjuvant for stage III colon, also stage II high-risk (T4 / lymphovascular invasion / <12 LN sampled / poorly diff). Metastatic 1L for RAS-WT right-sided OR RAS-mutant + bev (combined with bevacizumab) — see Indication entries for biologic-add-on logic.

Used By

Indication

IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX - IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX
IND-CRC-ADJUVANT-STAGE3-FOLFOX - IND-CRC-ADJUVANT-STAGE3-FOLFOX
IND-CRC-OLIGOMET-LIVER-LIMITED - IND-CRC-OLIGOMET-LIVER-LIMITED

Regimen

REG-ZANIDATAMAB - Zanidatamab — 2L+ HER2-amplified biliary tract cancer (HERIZON-BTC-01)